文献速递胸部肿瘤

EML4-ALK变异与合并TP53突变对ALK融合阳性NSCLC一线ALK酪氨酸激酶抑制剂治疗时长和总生存的影响:GuardantINFORM数据库真实世界结局

Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.
PubMed 文献 · J Thorac Oncol · 2024-07-15

在GuardantINFORM数据库中,307例晚期或转移性ALK融合阳性NSCLC患者接受一线下一代ALK TKI单药治疗,评估ctDNA中ALK融合VAF、EML4-ALK变异和TP53mt对至停药时间(TTD)的影响。VAF≥1%者中位TTD 14.7个月,VAF<1%者32.2个月(HR=1.57,p=0.0146);检出TP53mt者中位TTD 13.1个月,未检出者27.6个月(HR=1.53,p=0.0202);v1与v3的中位TTD无显著差异。结论认为高ctDNA VAF、EML4-ALK v3和TP53mt与一线ALK TKI早期停药相关。

要点

  • VAF≥1%者中位TTD 14.7个月,VAF<1%者32.2个月,HR=1.57(p=0.0146)。
  • 检出TP53mt者中位TTD 13.1个月,未检出者27.6个月,HR=1.53(p=0.0202)。
  • v1与v3的中位TTD分别为20.3与11.5个月,HR=1.29(p=0.2641),无显著差异。

核心结论

  • 高ctDNA VAF、EML4-ALK v3和TP53mt与一线ALK TKI早期停药相关。

研究设计与样本

  • 在GuardantINFORM数据库中识别接受一线下一代ALK TKI单药治疗的晚期或转移性NSCLC且ctDNA检出ALK融合的成人患者。
  • 共307例患者接受一线阿来替尼(n=280)、布格替尼(n=15)、洛拉替尼(n=9)或色瑞替尼(n=3)。
  • 评估ALK融合VAF、EML4-ALK变异和TP53mt检测对至停药时间(TTD)的影响。

主要发现

  • 150例(49%)患者ALK融合VAF≥1%。
  • 232例EML4-ALK融合患者中,v1占50%,v3占36%;TP53mt与v1共存42例(18%),与v3共存32例(14%)。
  • VAF<1%者中位TTD 32.2个月(95%CI:20.7-不可估计),VAF≥1%者14.7个月(95%CI:10.4-19.9),HR=1.57(95%CI:1.09-2.26),p=0.0146。
  • 检出TP53mt者中位TTD 13.1个月(95%CI:9.5-19.9),未检出者27.6个月(95%CI:17.3-不可估计),HR=1.53(95%CI:1.07-2.19),p=0.0202。
  • v1者中位TTD 20.3个月(95%CI:14.4-不可估计),v3者11.5个月(95%CI:7.4-31.1),HR=1.29(95%CI:0.83-2.01),p=0.2641,无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Tyrosine kinase inhibitors (TKIs) are first-line treatment options for ALK-positive (ALK+) NSCLC. Factors such as variant allele frequencies (VAFs), EML4-ALK fusion variant, and concurrent TP53 mutations (TP53mt) in circulating tumor DNA (ctDNA) may affect treatment outcomes. We evaluated their effects on time to discontinuation (TTD) of first-line treatment with next-generation ALK TKIs in a real-world setting. METHODS: Adults with advanced or metastatic NSCLC and ctDNA-detected ALK fusion who received first-line next-generation ALK TKI monotherapy were identified in GuardantINFORM. Effects of ALK fusion VAF, EML4-ALK variants, and TP53mt detection on TTD were evaluated. RESULTS: A total of 307 patients with ALK fusion in baseline ctDNA received first-line alectinib (n = 280), brigatinib (n = 15), lorlatinib (n = 9), or ceritinib (n = 3); 150 patients (49%) had ALK-fusion VAF greater than or equal to 1%. Among 232 patients with EML4-ALK fusions (v1, 50%; v3, 36%), TP53mt co-occurred with v1 in 42 (18%) and v3 in 32 (14%). Patients with VAF less than 1% versus greater than or equal to 1% had a median TTD of 32.2 (95% confidence interval [CI]: 20.7-not estimable [NE]) versus 14.7 months (10.4-19.9; hazard ratio [HR] = 1.57 [95% CI: 1.09-2.26]; p = 0.0146). Median TTD was 13.1 (9.5-19.9) versus 27.6 months (17.3-NE) in patients with versus without TP53mt detected (HR = 1.53 [1.07-2.19]; p = 0.0202) and 20.3 (14.4-NE) versus 11.5 months (7.4-31.1) in patients with v1 versus v3 (HR = 1.29 [0.83-2.01]; p = 0.2641). Patients with TP53mt and v3 had a median TTD of 7.4 months (95% CI: 4.2-31.1). CONCLUSION: High ctDNA VAF, EML4-ALK v3, and TP53mt were associated with early discontinuation of first-line ALK TKIs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Parikh K, Dimou A, Leventakos K, et al. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database. J Thorac Oncol. 2024. PMID: 39019326. doi:10.1016/j.jtho.2024.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。